<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38932251</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Antiviral Activity of Ag<sub>5</sub>IO<sub>6</sub>, a Unique Silver Compound.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">959</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16060959</ELocationID><Abstract><AbstractText>Pentasilver hexaoxoiodate (Ag<sub>5</sub>IO<sub>6</sub>) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study's goal was to determine whether it may also have antiviral activity against structurally distinct viruses. Ag<sub>5</sub>IO<sub>6</sub> was tested following ASTM E1052-20, Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension, against adenovirus type 5, murine norovirus, poliovirus type 1, SARS-CoV-2 (original), and SARS-CoV-2 (omicron) (host cells: H1HeLa, RAW 264.7, LLC-MK2, Vero E6, and Vero E6, respectively). A 0.1 g/mL Ag<sub>5</sub>IO<sub>6</sub> suspension was prepared and the viruses were exposed for 30 min, 4 h, or 24 h. Exposure to Ag<sub>5</sub>IO<sub>6</sub> resulted in complete kill of SARS-CoV-2 (omicron) within 30 min, as well as complete kill of both SARS-CoV-2 (original) and the murine norovirus within 4 h. Ag<sub>5</sub>IO<sub>6</sub> showed increasing activity over time against the adenovirus, but did not achieve a 3-log reduction within 24 h, and showed no antiviral activity against the poliovirus. These results demonstrate that Ag<sub>5</sub>IO<sub>6</sub> has antiviral activity against medically important viruses, in addition to its well-characterized antimicrobial activity, suggesting that it may be valuable in situations where the prevention or simultaneous treatment of microbes and viruses are necessary.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Mauri</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nelson Laboratories Bozeman, LLC, 1765 S. 19th Avenue, Bozeman, MT 59718, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boone</LastName><ForeName>Tyler J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Innovotech, Inc., Suite L131, 2011-94 St. NW, Edmonton, AL T6N 1H1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadworny</LastName><ForeName>Patricia L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-4065-3917</Identifier><AffiliationInfo><Affiliation>Innovotech, Inc., Suite L131, 2011-94 St. NW, Edmonton, AL T6N 1H1, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>232403038</GrantID><Agency>Alberta Innovates</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018030">Silver Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018030" MajorTopicYN="N">Silver Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029322" MajorTopicYN="N">Norovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067996" MajorTopicYN="N">RAW 264.7 Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">InnovoSIL™-1 silver</Keyword><Keyword MajorTopicYN="N">anti-adherence</Keyword><Keyword MajorTopicYN="N">antibiofilm</Keyword><Keyword MajorTopicYN="N">antimicrobial coating</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">nanostructured silver</Keyword><Keyword MajorTopicYN="N">pentasilver hexaoxoiodate</Keyword><Keyword MajorTopicYN="N">silver periodate</Keyword><Keyword MajorTopicYN="N">virucidal</Keyword></KeywordList><CoiStatement>Authors P.L.N. and T.J.B. are employees of, and own stocks in, Innovotech, Inc. Author P.L.N. is the inventor on multiple patents and patents-pending related to Ag<sub>5</sub>IO<sub>6</sub>, including the patent listed above. The remaining author, M.E., declares no conflicts of interest. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38932251</ArticleId><ArticleId IdType="pmc">PMC11209601</ArticleId><ArticleId IdType="doi">10.3390/v16060959</ArticleId><ArticleId IdType="pii">v16060959</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prestinaci F., Pezzotti P., Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog. Glob. Health. 2015;109:309–318. doi: 10.1179/2047773215Y.0000000030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/2047773215Y.0000000030</ArticleId><ArticleId IdType="pmc">PMC4768623</ArticleId><ArticleId IdType="pubmed">26343252</ArticleId></ArticleIdList></Reference><Reference><Citation>Grier N. Silver and its compounds. In: Block S., editor. Disinfection, Sterilization and Preservation. 3rd ed. Lea &amp; Febiger; Philadelphia, PA, USA: 1983. pp. 375–389.</Citation></Reference><Reference><Citation>Taylor P.L., Ussher A.L., Burrell R.E. Impact of heat on nanocrystalline silver dressings. Part I: Chemical and biological properties. Biomaterials. 2005;26:7221–7229. doi: 10.1016/j.biomaterials.2005.05.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2005.05.040</ArticleId><ArticleId IdType="pubmed">16005512</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadworny P.L., Burrell R.E. A review of assessment techniques for silver technology in wound care. Part 1: In vitro methods for assessing antimicrobial activity. J. Wound Tech. 2008;1:6–13.</Citation></Reference><Reference><Citation>Gallant-Behm C.L., Yin H.Q., Liu S.J., Heggers J.P., Langford R.E., Olson M.E., Hart D.A., Burrell R.E. Comparison of in vitro disc diffusion and time kill-kinetic assays for the evaluation of antimicrobial wound dressing efficacy. Wound Rep. Regen. 2005;13:412–421. doi: 10.1111/j.1067-1927.2005.130409.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1067-1927.2005.130409.x</ArticleId><ArticleId IdType="pubmed">16008731</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavanagh M.H., Burrell R.E., Nadworny P.L. Evaluating antimicrobial efficacy of new commercially available silver dressings. Int. Wound J. 2010;7:394–405. doi: 10.1111/j.1742-481X.2010.00705.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-481X.2010.00705.x</ArticleId><ArticleId IdType="pmc">PMC7951607</ArticleId><ArticleId IdType="pubmed">20626470</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips P.L., Yang Q., Davis S., Sampson E.M., Azeke J.I., Hamad A., Schultz G.S. Antimicrobial dressing efficacy against mature Pseudomonas aeruginosa biofilm on porcine skin explants. Int. Wound J. 2015;12:469–483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7950379</ArticleId><ArticleId IdType="pubmed">24028432</ArticleId></ArticleIdList></Reference><Reference><Citation>Incani V., Omar A., Prosperi-Porta G., Nadworny P. Ag5IO6: Novel antibiofilm activity of a silver compound with application to medical devices. Int. J. Antimicrob. Agents. 2015;45:586–593. doi: 10.1016/j.ijantimicag.2014.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2014.09.008</ArticleId><ArticleId IdType="pubmed">25604278</ArticleId></ArticleIdList></Reference><Reference><Citation>Cignini P., Icovi M., Panero S., Pistoia G. On the possibility of using silver salts other than Ag2CrO4 in organic lithium cells. J. Power Sources. 1978;3:347–357. doi: 10.1016/0378-7753(78)80023-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-7753(78)80023-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalevskiy A., Jansen M. Synthesis, crystal structure determination, and physical properties of Ag5IO6. Z. Anorg. Allg. Chem. 2006;632:577–581. doi: 10.1002/zaac.200500476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/zaac.200500476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadworny P.L., Prosperi-Porta G., Unrau K.R. Method for Producing Silver(I) Orthoperiodates. WO2014029013A1. Patent. 2014 February 27;</Citation></Reference><Reference><Citation>Olson M.E., Nadworny P.L., Prosperi-Porta G. Antimicrobial Silver Iodate. 11,766,505. U.S. Patent. 2023 September 26;</Citation></Reference><Reference><Citation>Olson M.E., Nadworny P.L., Prosperi-Porta G. Antimicrobial Silver Iodate. 11,116,865. U.S. Patent. 2021 September 14;</Citation></Reference><Reference><Citation>Olson M.E., Anderson J.J., Omar A.M., Nadworny P.L. Silver Iodate Compounds Having Antimicrobial Properties. 2 605 659 B1. European Patent. 2020 July 23;</Citation></Reference><Reference><Citation>Olson M.E., Nadworny P.L., Omar A.M., Cabrera Y.E. Family of Silver(I) Periodate Compounds Having Broad Microbial Properties. 9,723,843. U.S. Patent. 2017 August 8;</Citation></Reference><Reference><Citation>Olson M.E., Nadworny P.L., Prosperi-Porta G. Antimicrobial Silver Iodate. 10,434,210. U.S. Patent. 2019 October 8;</Citation></Reference><Reference><Citation>Nadworny P.L., Hickerson W.L., Holley-Harrison H.D., Bloom D.C., Grams T.R., Edwards T.G., Schultz G.S., Burrell R.E. Treatment of infection and inflammation associated with COVID-19, multi-drug resistant pneumonia and fungal sinusitis by nebulizing a nanosilver solution. Nanomedicine. 2023;48:102654. doi: 10.1016/j.nano.2023.102654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2023.102654</ArticleId><ArticleId IdType="pmc">PMC9839457</ArticleId><ArticleId IdType="pubmed">36646192</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadworny P.L. Ph.D. Thesis. University of Alberta; Edmonton, AB, Canada: 2009. Biological Activity of Nanostructured Silver.</Citation></Reference><Reference><Citation>Department of Health and Human Services (HSS) Public Health Service (PHS) Food and Drug Administration (FDA) Over-the-counter drug products containing colloidal silver ingredients or silver salts. Final rule. Fed. Regist. 1999;64:44653–44658.</Citation><ArticleIdList><ArticleId IdType="pubmed">10558603</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh K.A., Chen K.L. Aggregation kinetics of citrate and polyvinylpyrrolidone coated silver nanoparticles in monovalent and divalent electrolyte solutions. Environ. Sci. Technol. 2011;45:5564–5571. doi: 10.1021/es200157h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/es200157h</ArticleId><ArticleId IdType="pmc">PMC3137917</ArticleId><ArticleId IdType="pubmed">21630686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Quinsaat J.E.Q., Li F., Isono T., Tajima K., Satoh T., Sato S.-I., Yamamoto T. Size control and enhanced stability of silver nanoparticles by cyclic poly(ethylene glycol) Polymers. 2022;14:4535. doi: 10.3390/polym14214535.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym14214535</ArticleId><ArticleId IdType="pmc">PMC9657728</ArticleId><ArticleId IdType="pubmed">36365529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung J.H., Ji J.H., Park J.D., Yoon J.U., Kim D.S., Jeon K.S., Song M.Y., Jeong J., Han B.S., Han J.H., et al. Subchronic inhalation toxicity of silver nanoparticles. Toxicol. Sci. 2009;108:452–461. doi: 10.1093/toxsci/kfn246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/toxsci/kfn246</ArticleId><ArticleId IdType="pubmed">19033393</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston H.J., Hutchison G., Christensen F.M., Peters S., Hankin S., Stone V. A review of the in vivo and in vitro toxicity of silver and gold particulates: Particle attributes and biological mechanisms responsible for the observed toxicity. Crit. Rev. Toxicol. 2010;40:328–346. doi: 10.3109/10408440903453074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10408440903453074</ArticleId><ArticleId IdType="pubmed">20128631</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadworny P.L., Wang J.F., Tredget E.E., Burrell R.E. Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model. Nanomed. Nanotechnol. Biol. Med. 2008;4:241–251. doi: 10.1016/j.nano.2008.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2008.04.006</ArticleId><ArticleId IdType="pubmed">18550449</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadworny P.L., Shrum J., Christensen N., McCaffrey W.C., Burrell R.E. Antimicrobial activity of nanocrystalline silver: The role of grain boundary atoms; Proceedings of the 6th Alberta BME Conference; Banff, AB, Canada. 21–23 October 2005.</Citation></Reference><Reference><Citation>Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension. ASTM; West Conshohocken, PA, USA: 2020. p. 4.</Citation></Reference><Reference><Citation>Lei C., Yang J., Hu J., Sun X. On the calculation of TCID(50) for quantitation of virus infectivity. Virol. Sin. 2021;36:141–144. doi: 10.1007/s12250-020-00230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00230-5</ArticleId><ArticleId IdType="pmc">PMC7973348</ArticleId><ArticleId IdType="pubmed">32458296</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell A.D., Hugo W.B. Antimicrobial activity and action of silver. Prog. Med. Chem. 1994;31:351–370.</Citation><ArticleIdList><ArticleId IdType="pubmed">8029478</ArticleId></ArticleIdList></Reference><Reference><Citation>Naqvi S.H.S., Citardi M.J., Cattano D., Ostrosky-Zeichner L., Knackstedt M.I., Karni R.J. Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework. J. Otolaryngol. Head. Neck Surg. 2020;49:77–80. doi: 10.1186/s40463-020-00474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40463-020-00474-x</ArticleId><ArticleId IdType="pmc">PMC7590913</ArticleId><ArticleId IdType="pubmed">33109269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra A., Sivaraman K., Radhakrishnan R., Balakrishnan D., Narayana A. Can povidone iodine gargle/mouthrinse inactivate SARS-CoV-2 and decrease the risk of nosocomial and community transmission during the COVID-19 pandemic? An evidence-based update. Jpn. Dent. Sci. Rev. 2021;57:39–45. doi: 10.1016/j.jdsr.2021.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdsr.2021.03.001</ArticleId><ArticleId IdType="pmc">PMC7959263</ArticleId><ArticleId IdType="pubmed">33747261</ArticleId></ArticleIdList></Reference><Reference><Citation>Galdiero S., Falanga A., Vitiello M., Cantisani M., Marra V., Galdiero M. Silver nanoparticles as potential antiviral agents. Molecules. 2011;16:8894–8918. doi: 10.3390/molecules16108894.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules16108894</ArticleId><ArticleId IdType="pmc">PMC6264685</ArticleId><ArticleId IdType="pubmed">22024958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Q., Lim J.Y.C., Xue K., Yew P.Y.M., Owh C., Chee P.L., Loh X.J. Sanitizing agents for virus inactivation and disinfection. View. 2020;1:e16. doi: 10.1002/viw2.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/viw2.16</ArticleId><ArticleId IdType="pmc">PMC7267133</ArticleId><ArticleId IdType="pubmed">34766164</ArticleId></ArticleIdList></Reference><Reference><Citation>Slawson R.M., Trevors J.T., Lee H. Silver accumulation and resistance in Pseudomonas stutzeri. Arch. Microbiol. 1992;158:398–404. doi: 10.1007/BF00276299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00276299</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadworny P.L., Burrell R.E. A review of assessment techniques for silver technology in wound care. Part 2: Tissue culture and in vivo methods for determining antimicrobial and anti-inflammatory activity. J. Wound Tech. 2008;1:13–22.</Citation></Reference><Reference><Citation>Ershov V., Tarasova N., Abkhalimov E., Safonov A., Sorokin V., Ershov B. Photochemical synthesis of silver hydrosol stabilized by carbonate ions and study of its bactericidal impact on Escherichia coli: Direct and indirect effects. Int. J. Mol. Sci. 2022;23:949. doi: 10.3390/ijms23020949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23020949</ArticleId><ArticleId IdType="pmc">PMC8780126</ArticleId><ArticleId IdType="pubmed">35055135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamurthy C.H., Padma M., Samadanam I.D.M., Mareeswaran R., Suyavaran A., Kumar M.S., Premkumar K., Thirunavukkarasu C. The extra cellular synthesis of gold and silver nanoparticles and their free radical scavenging and antibacterial properties. Colloids Surf. B Biointerfaces. 2013;102:808–815. doi: 10.1016/j.colsurfb.2012.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2012.09.025</ArticleId><ArticleId IdType="pubmed">23107960</ArticleId></ArticleIdList></Reference><Reference><Citation>Bragg P.D., Rainnie D.J. The effect of silver ions on the respiratory chain of Escherichia coli. Can. J. Microbiol. 1974;20:883–889. doi: 10.1139/m74-135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/m74-135</ArticleId><ArticleId IdType="pubmed">4151872</ArticleId></ArticleIdList></Reference><Reference><Citation>Modak S.M., Fox C.L., Jr. Binding of silver sulfadiazine to the cellular components of Pseudomonas aeruginosa. Biochem. Pharmacol. 1973;22:2391–2404. doi: 10.1016/0006-2952(73)90341-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-2952(73)90341-9</ArticleId><ArticleId IdType="pubmed">4200887</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the treatment of COVID-19—Final report. N. Engl. J. Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Thompson B.T. Dexamethasone in hospitalised patients with COVID-19: Addressing uncertainties. Lancet Respir. Med. 2020;8:1170–1172. doi: 10.1016/S2213-2600(20)30503-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30503-8</ArticleId><ArticleId IdType="pmc">PMC7598750</ArticleId><ArticleId IdType="pubmed">33129421</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration  Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid™ 2021.  [(accessed on 10 June 2024)];2021  Available online:  https://www.fda.gov/media/155050/download.</Citation></Reference><Reference><Citation>Garcia-Beltran W.F., St Denis K.J., Hoelzemer A., Lam E.C., Nitido A.D., Sheehan M.L., Berrios C., Ofoman O., Chang C.C., Hauser B.M., et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185:457–466. doi: 10.1016/j.cell.2021.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirvanimoghaddam K., Akbari M.K., Yadav R., Al-Tamimi A.K., Naebe M. Fight against COVID-19: The case of antiviral surfaces. APL Mater. 2021;9:031112. doi: 10.1063/5.0043009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/5.0043009</ArticleId><ArticleId IdType="pmc">PMC8017599</ArticleId><ArticleId IdType="pubmed">33842101</ArticleId></ArticleIdList></Reference><Reference><Citation>Unrau K.R. Master’s Thesis. University of Alberta; Edmonton, AB, Canada: 2012. Activity of Nanocrystalline Gold and Silver Alloys.</Citation></Reference><Reference><Citation>Mathews S., Hans M., Mucklich F., Solioz M. Contact killing of bacteria on copper is suppressed if bacterial-metal contact is prevented and is induced on iron by copper ions. Appl. Env. Micro. 2013;79:2605–2611. doi: 10.1128/AEM.03608-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.03608-12</ArticleId><ArticleId IdType="pmc">PMC3623184</ArticleId><ArticleId IdType="pubmed">23396344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeremiah S.S., Miyakawa K., Morita T., Yamaoka Y., Ryo A. Potent antiviral effect of silver nanoparticles on SARS-CoV-2. Biochem. Biophys. Res. Commun. 2020;533:195–200. doi: 10.1016/j.bbrc.2020.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.09.018</ArticleId><ArticleId IdType="pmc">PMC7486059</ArticleId><ArticleId IdType="pubmed">32958250</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Borowski R.G., Trentin D.S. Biofilms and coronavirus reservoirs: A perspective review. Appl. Environ. Microbiol. 2021;87:e0085921. doi: 10.1128/AEM.00859-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00859-21</ArticleId><ArticleId IdType="pmc">PMC8388801</ArticleId><ArticleId IdType="pubmed">34190608</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoulouze M.I., Alcover A. Can viruses form biofilms? Trends Microbiol. 2011;19:257–262. doi: 10.1016/j.tim.2011.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2011.03.002</ArticleId><ArticleId IdType="pubmed">21458997</ArticleId></ArticleIdList></Reference><Reference><Citation>Arone C., Martial S., Burlaud-Gaillard J., Thoulouze M.I., Roingeard P., Dutartre H., Muriaux D. HTLV-1 biofilm polarization maintained by tetraspanin CD82 is required for efficient viral transmission. mBio. 2023;14:e0132623. doi: 10.1128/mbio.01326-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01326-23</ArticleId><ArticleId IdType="pmc">PMC10746275</ArticleId><ArticleId IdType="pubmed">37889017</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>